Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-Up of RGX-314 for Diabetic Retinopathy
NCT05296447Phase 2Enrolling by invitation
- Sponsor
- AbbVie Inc.
- Start
- Apr 2022
- Primary completion
- Jun 2031
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
A Phase 2 trial of surabgene lomparvovec in diabetic retinopathy (DR), sponsored by AbbVie Inc.. Started Apr 2022; status: enrolling by invitation.
02
Drugs
surabgene lomparvovec
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT05296447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05296447.